本帖最后由 老马 于 2013-3-13 13:43 编辑 1 K5 g; M/ D0 X$ E3 W- Y
9 E$ ^/ c4 Y3 w' C5 ?% z健择(吉西他滨)+顺铂+阿瓦斯汀! C6 w, Y h6 T' I1 {' f Z
Gemzar +Cisplatin + Avastin/ y/ Y6 w0 c( y: v; W
http://annonc.oxfordjournals.org/content/21/9/1804.full
6 K0 ]- x; f) t2 n7 }Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 3 { c8 n. C0 c+ \0 j# d4 R9 t6 s
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ' q* F+ H8 t9 t: b$ }& v7 _
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* B) @" O4 S6 o- q5 k8 O5 p- H- ^- B
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 905)
6 y, k+ y; z% |* W
华为网盘附件:8 T- i7 l0 e2 e: C- Z$ m, u6 f
【华为网盘】ava.JPG
) K& I7 L/ r1 ^" H+ X& K/ R4 }# E- f+ S |